Every 43 seconds, an American suffers a heart attack. 

This was CNN’s headline on May 17th, 2016.

What’s more scary is 50% of them are “silent attacks”, meaning you are unaware of them and they can only be detected by “troponin” in your blood. People with these attacks are 3 times more to die because of these silent killers.

It sounds horrifying but we can change that.

MobioSense is here to change that. 


MobioSense joins 2017 Pulse@MassChallenge's cohort.

MassChallenge, the most startup-friendly accelerator on the planet, today announced the 31 startups joining PULSE@MassChallenge’s inaugural cohort. Representing the most innovative digital health technologies, these startups were selected from more than 430 applicants from 30 states and 20 countries around the world. 

Through rigorous matchmaking, the first-ever cohort was selected by an impressive pool of institutions, corporations, payors, and healthcare partners looking to form unique partnerships with digital health startups. These Champions will support entrepreneurs working out of PULSE@MassChallenge’s 8,000 square-foot innovation lab by facilitating key advisor introductions, pilots, research, and even investment opportunities over the course of six months. At the culmination of the program, startups will compete for more than $100,000 in zero-equity awards. 

43 North Finalist

HERO is proud to be a 43North finalist.

Come see MobioSense at the 43North Finals week 10/26/2016~ 10/27/2016. Let MobioSense show you a tomorrow where you can see your numbers, know your numbers and prevent future attacks.


Saving lives, 24/7, anywhere, anytime.

HERO provides instant & affordable heart disease monitoring.

HERO brings you a future where we prevent acute attacks before they happen. 

HERO prevents and predicts heart attacks with the latest and most accurate Troponin biochips. A revolutionary biochip 100 times more sensitive than what we have in hospitals now-- all at your disposal at a price of a Latte.

With HERO, you can see your numbers and conquer your disease, 24/7, anywhere, anytime.